Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome

MLA

Anna Dodero, et al. “Dose-Adjusted EPOCH and Rituximab for the Treatment of Double Expressor and Double-Hit Diffuse Large B-Cell Lymphoma: Impact of TP53 Mutations on Clinical Outcome.” Haematologica, vol. 107, no. 5, July 2021. EBSCOhost, https://doi.org/10.3324/haematol.2021.278638.

APA

Anna Dodero, Anna Guidetti, Fabrizio Marino, Alessandra Tucci, Francesco Barretta, Alessandro Re, Monica Balzarotti, Cristiana Carniti, Chiara Monfrini, Annalisa Chiappella, Antonello Cabras, Fabio Facchetti, Martina Pennisi, Daoud Rahal, Valentina Monti, Liliana Devizzi, Rosalba Miceli, Federica Cocito, Lucia Farina, … Paolo Corradini. (2021). Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Haematologica, 107(5). https://doi.org/10.3324/haematol.2021.278638

Chicago

Anna Dodero, Anna Guidetti, Fabrizio Marino, Alessandra Tucci, Francesco Barretta, Alessandro Re, Monica Balzarotti, et al. 2021. “Dose-Adjusted EPOCH and Rituximab for the Treatment of Double Expressor and Double-Hit Diffuse Large B-Cell Lymphoma: Impact of TP53 Mutations on Clinical Outcome.” Haematologica 107 (5). doi:10.3324/haematol.2021.278638.